StockData
ABVC BioPharma, Inc. logo

ABVC BioPharma, Inc. (ABVC) stock

ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.91−0.03 (-3.15%)

Close on Nov 18, 2026Market cap $24.27MP/E –Yield –

ABVC BioPharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ABVC BioPharma's free cash flow for the twelve months ending Dec 31, 2023 was -$4.21M. For fiscal 2023 it was -$4.21M. The highest annual figure on record is -$37.77K in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$4.21M–
FY2022Dec 31, 2022-$7.52M–
FY2021Dec 31, 2021-$7.62M–
FY2013Sep 30, 2013-$37.77K–
FY2012Sep 30, 2012-$915.47K–
FY2011Sep 30, 2011-$1.62M–
FY2010Sep 30, 2010-$1.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2023CQ4 2023Dec 31, 2023-$430.46K–
Q4 FY2022CQ4 2022Dec 31, 2022-$461.16K–
Q3 FY2022CQ3 2022Sep 30, 2022-$518.06K–
Q2 FY2022CQ2 2022Jun 30, 2022-$3.45M–
Q1 FY2022CQ1 2022Mar 31, 2022-$3.09M–
Q4 FY2021CQ4 2021Dec 31, 2021-$2.52M–

More ABVC BioPharma figures

See a number that looks wrong?